AbbVie Inc. (NYSE:ABBV) is expected to pay $0.57 on Nov 15, 2016. The indicated annual dividend is $2.28. Shareholders owning the stock before Oct 12, 2016 will be eligible to receive the payout. Based on AbbVie Inc.’s current price of $63.31, the dividend is 0.90%. This dividend’s record date is Oct 14, 2016 and the announcement date is Sep 9, 2016. The stock increased 0.60% or $0.38 during the last trading session, hitting $63.31. AbbVie Inc (NYSE:ABBV) has risen 14.44% since March 8, 2016 and is uptrending. It has outperformed by 5.13% the S&P500.
AbbVie Inc. is a research-based biopharmaceutical company. The company has a market cap of $103.27 billion. The Firm develops and markets therapies that address a range of diseases. It has a 18.15 P/E ratio. The Firm operates in pharmaceutical products segment.
Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.29, from 1.15 in 2016Q1. The ratio worsened, as 86 funds sold all AbbVie Inc shares owned while 593 reduced positions. 75 funds bought stakes while 508 increased positions. They now own 1.06 billion shares or 1.95% less from 1.08 billion shares in 2016Q1.
Clifford Swan Invest Counsel Limited Liability Company has 0.87% invested in the company for 202,851 shares. Sawgrass Asset Limited Com holds 1.16% or 402,725 shares in its portfolio. Auxier Asset accumulated 0.29% or 20,672 shares. Dnb Asset Mgmt As accumulated 0% or 136,795 shares. Quantbot Technologies Lp has 0.18% invested in the company for 26,640 shares. Old Mutual Customised Solutions (Proprietary) Limited, a South Africa-based fund reported 6,500 shares. Teachers Advisors has 0.3% invested in the company for 2.76M shares. Nomura Asset Co reported 503,094 shares or 0.58% of all its holdings. Copeland Cap Limited Liability Corporation accumulated 5,406 shares or 0.02% of the stock. Cordasco Financial Net last reported 0.14% of its portfolio in the stock. Signature Fincl Mngmt Incorporated holds 4,471 shares or 0.13% of its portfolio. The Washington-based Badgley Phelps And Bell has invested 0.02% in AbbVie Inc (NYSE:ABBV). Diversified Trust holds 0.08% of its portfolio in AbbVie Inc (NYSE:ABBV) for 11,735 shares. A D Beadell Investment Counsel holds 1.97% or 38,870 shares in its portfolio. Sfe Investment Counsel has invested 3.16% of its portfolio in AbbVie Inc (NYSE:ABBV).
Insider Transactions: Since May 10, 2016, the stock had 0 insider buys, and 6 insider sales for $28.75 million net activity. Schumacher Laura J sold $3.25 million worth of stock. RICHMOND TIMOTHY J. sold $1.37M worth of stock or 21,583 shares. $2.49 million worth of AbbVie Inc (NYSE:ABBV) shares were sold by GONZALEZ RICHARD A. $381,541 worth of AbbVie Inc (NYSE:ABBV) was sold by HURWICH THOMAS A.. ALBAN CARLOS also sold $3.01M worth of AbbVie Inc (NYSE:ABBV) on Tuesday, May 10.
AbbVie Inc (NYSE:ABBV) Ratings Coverage
Out of 15 analysts covering Abbvie Inc (NYSE:ABBV), 7 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 47% are positive. $85 is the highest target while $55 is the lowest. The $71.17 average target is 12.42% above today’s ($63.31) stock price. Abbvie Inc has been the topic of 27 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of AbbVie Inc (NYSE:ABBV) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, June 8. Jefferies upgraded AbbVie Inc (NYSE:ABBV) rating on Monday, December 7. Jefferies has “Buy” rating and $55 price target. Atlantic Securities initiated the stock with “Neutral” rating in Friday, December 18 report. The stock of AbbVie Inc (NYSE:ABBV) earned “Outperform” rating by William Blair on Friday, February 5. Raymond James initiated the shares of ABBV in a report on Friday, September 2 with “Outperform” rating. Deutsche Bank initiated it with “Hold” rating and $63 target price in Tuesday, March 15 report. The stock has “Buy” rating given by Goldman Sachs on Monday, March 7. The stock of AbbVie Inc (NYSE:ABBV) earned “Sell” rating by Societe Generale on Wednesday, April 6. The firm has “Buy” rating by UBS given on Friday, October 23. The company was downgraded on Thursday, September 8 by JP Morgan.
More news for AbbVie Inc (NYSE:ABBV) were recently published by: Fool.com, which released: “Better Buy: Pfizer Inc. vs. AbbVie Inc.” on September 15, 2016. Seekingalpha.com‘s article titled: “AbbVie Is An Enigma Stock That Keeps Paying Dividends” and published on October 09, 2016 is yet another important article.
ABBV Company Profile
AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research biopharmaceutical company. The Firm develops and markets therapies that address a range of diseases. The Firm operates in pharmaceutical products segment. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications in clinical development across medical specialties, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.